KENNEWICK, WA / ACCESSWIRE / July 11, 2016 / Advanced Medical Isotope Corporation (or "AMI") (ADMD), a late stage radiation oncology focused medical device company today announced that it has partnered with Versant Medical Physics and Radiation Safety company to provide dosimetry expertise to support development of the Company's brachytherapy devices.
Versant, a provider of comprehensive medical physics consulting services, will provide AMI with expert scientific and technical support on dosimetry, which is the calculation and assessment of the radiation dose received by the human body, for AMI's medical devices.
AMI Founder, CEO and Chairman James C. Katzaroff stated, "In the development and commercialization of devices that use radiation for therapeutic purposes, it is critical to partner with expert medical physicists to develop treatment plans that provide appropriate dose calculations. We are pleased to formalize a relationship with Versant to provide these key services."
This formal relationship between AMI and Versant provides AMI access to experts in medical physics and dosimetry, including Versant physicist Dr. Darrell Fisher. The relationship with Versant provides a formal manner for Dr. Fisher to engage with AMI in a more meaningful and impactful way. Dr. Fisher has previously provided AMI with key input on product development including regulatory and commercialization issues and holds seven patents, including patents licensed by AMI for its brachytherapy products.
Dr. Fisher is known internationally for his expertise in the dosimetry and effects of radioactive materials, including medically administered radiopharmaceuticals for diagnostic and therapeutic benefit. Dr. Fisher is a recent president of the Health Physics Society, an international organization of professionals engaged in the science and practice of radiation safety. He also serves on the Medical Internal Radiation Dose Committee of the Society of Nuclear Medicine and Molecular Imaging, which develops standard methods for radiopharmaceutical dosimetry. Dr. Fisher previously served on the U.S. Nuclear Regulatory Commission's Advisory Committee on the Medical Uses of Isotopes. He recently completed a 35-year career at the Pacific Northwest National Laboratory (PNNL).
Marcie Ramsay, Managing Director of Versant Medical Physics and Radiation Safety said, "Versant is delighted to enter into this relationship with Advanced Medical Isotope Corporation. Our nuclear medicine team consists of well-known experts who have been working in the industry for many years. These specialists have been providing support to teams studying the medical benefits of radioactive treatments. This collaborative effort will support both companies to achieve our growth objectives in the foreseeable future."
About Advanced Medical Isotope Corporation
Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non resectable tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our website, www.isotopeworld.com.
About Versant Medical Physics and Radiation Safety
Headquartered in Kalamazoo, MI, Versant Medical Physics and Radiation Safety provides superior quality consulting services to health care providers. A woman-owned small business at the forefront of the medical physics industry, Versant's mission is to produce highly accurate, efficient results to ultimately improve the quality of its clients', and their patients', lives. The Company offers a comprehensive line of services that includes Therapy Physics, Commissioning, Radiation Safety Officer (RSO), Safety Training, Internal Dose, Diagnostic QA, Regulatory Support, as well as Remote and Onsite Dosimetry. Offering remote treatment planning services gives secure, individualized attention with start to finish planning and contouring support.
For more information about Versant, please visit www.versantphysics.com.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.
Advanced Medical Isotope Corporation
James C. Katzaroff, CEO
1021 N Kellogg
Kennewick WA 99336
Versant Medical Physics and Radiation Safety
Bethany Richard, Public Relations
251 North Rose Street, Suite #200
Kalamazoo, MI 49007
SOURCE: Advanced Medical Isotope Corporation